Evaluation of Some of the Antibiotics in the Management of Hepatic Encephalopathy (HE): An Overview
Keywords:
Hepatic Encephalopathy, Neomycin, Rifaximin, metronidazole, Vancomycin, Probiotics.Abstract
Hepatic encephalopathy (HE) is a common complication among patients with liver cirrhosis associated with a high mortality rate. It is marked by fluctuating neuropsychiatric and cognitive impairment, which can be severe and life threatening. Liver cirrhosis is a leading cause of morbidity and mortality worldwide but exact prevalence of cirrhosis is not known. Prevalence of HE, also known as portosystemic encephalopathy (PSE), is 24% in cirrhotic patients. The diagnosis remains largely clinical, with the exclusion of possible other causes for the altered mental status. Symptoms of HE include attention deficits, alterations of sleep patterns and muscular incoordination progressing to stupor and coma. The pathogenesis of HE is still unidentified, although ammonia-induced variations of cerebral neurotransmitter balance, particularly at the astrocyte-neurone edge, may play a major role. Treatment of HE is therefore focused at reducing the manufacture and absorption of gut-derived neurotoxic substances, especially ammonia. Current treatment strategies include antibiotics such as neomycin, rifaximin, metronidazole, vancomycin and probiotics. The present review focuses on the pathogenesis, pathophysiology, diagnosis and management of HE.
Keywords: hepatic encephalopathy (HE), metronidazole, neomycin, probiotics, rifaximin, vancomycin
Cite this Article
Asad Jamal Ansari, Nishat Fatima, Mohammad Monawwar, Mohd Imran, Shweta, Shayna Bano, Alhamd Tanveer. Evaluation of Some of the Antibiotics in the Management of Hepatic Encephalopathy (HE): An Overview. Research & Reviews: A Journal of Pharmacology. 2020; 10(3): 22–39p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
